相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug rechanneling: A novel paradigm for cancer treatment
Itishree Kaushik et al.
SEMINARS IN CANCER BIOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
Paola Ostano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Mechanisms of action of currently used antiseizure drugs
Graeme J. Sills et al.
NEUROPHARMACOLOGY (2020)
Should mast cells be considered therapeutic targets in multiple sclerosis?
Karen Henriette Pinke et al.
NEURAL REGENERATION RESEARCH (2020)
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Fengzhi Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A Favorable Response to Levetiracetam in a Patient with Metastatic Adenoid Cystic Carcinoma
Shinya Sakata et al.
INTERNAL MEDICINE (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma
Edmund C. P. Chedgy et al.
JOURNAL OF PATHOLOGY (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Mast Cells as Drivers of Disease and Therapeutic Targets
Frank Siebenhaar et al.
TRENDS IN IMMUNOLOGY (2018)
Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer
Elena Jachetti et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Drug Repositioning for Effective Prostate Cancer Treatment
Beste Turanli et al.
FRONTIERS IN PHYSIOLOGY (2018)
Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β
Elena Jachetti et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
Min Zou et al.
CANCER DISCOVERY (2017)
Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers
Giorgio Mauri et al.
ONCOTARGET (2016)
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Caroline Happold et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Epigenetic modulators as therapeutic targets in prostate cancer
Ines Graca et al.
CLINICAL EPIGENETICS (2016)
Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
Hai-Bo Xi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer
Pawel Wiechno et al.
EUROPEAN UROLOGY (2014)
The many faces of neuroendocrine differentiation in prostate cancer progression
Stephane Terry et al.
FRONTIERS IN ONCOLOGY (2014)
Overdose with levetiracetam: a case report and review of the literature
T. M. Larkin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated From Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors
Stefania Mazzoleni et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer
Mark Stettner et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2012)
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
Pascal E. Sanchez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers
Paola Pittoni et al.
CANCER RESEARCH (2011)
Spotlight on Levetiracetam in Epilepsy
Katherine A. Lyseng-Williamson
CNS DRUGS (2011)
Effect of levetiracetam on hippocampal protein expression and cell proliferation in rats
Linda Paulson et al.
EPILEPSY RESEARCH (2010)
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide
George C. Bobustuc et al.
NEURO-ONCOLOGY (2010)
Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
Steffen Durinck et al.
NATURE PROTOCOLS (2009)
Botulinum Toxin Type A Inhibits the Growth of LNCaP Human Prostate Cancer Cells InVitro and InVivo
Gilles Karsenty et al.
PROSTATE (2009)
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer
Teresa Chiaverotti et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Origin of androgen-insensitive poorly differentiated tumors in the Transgenic adenocarcinoma of mouse prostate model
Wendy J. Huss et al.
NEOPLASIA (2007)
Accidental overdosage of levetiracetam in two children caused no side effects
Yasser Awaad
EPILEPSY & BEHAVIOR (2007)
SV2 is the protein receptor for botulinum neurotoxin A
M Dong et al.
SCIENCE (2006)
The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]i increase induced by ATP and bradykinin in PC12 cells
M Cataldi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The activity of antiepileptic drugs as histone deacetylase inhibitors
S Eyal et al.
EPILEPSIA (2004)
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
BA Lynch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy
S Pal et al.
CELL CALCIUM (2001)
Synaptic vesicle protein 2, a new neuroendocrine cell marker
GM Portela-Gomes et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
